Related Experiment Videos
Thymosin therapy in the DiGeorge syndrome
The Journal of Pediatrics
|July 1, 1980
Summary
Thymosin fraction 5 shows promise for treating DiGeorge syndrome immune defects. This thymus extract improved T-cell numbers and function in children, offering a potential alternative to risky fetal thymus transplants.
Area of Science:
- Immunology
- Developmental Biology
- Pediatrics
Background:
- DiGeorge syndrome is characterized by T-cell immune defects.
- Fetal thymus transplantation is a past treatment but carries risks like graft-versus-host reactions.
- Alternative therapies are needed for immune reconstruction in DiGeorge syndrome.
Purpose of the Study:
- To evaluate the efficacy of thymosin fraction 5 (thymosin F5) in improving immune function in children with DiGeorge syndrome.
- To assess both in vitro and in vivo effects of thymosin F5 on T-cell parameters.
Main Methods:
- Children with DiGeorge syndrome received thymosin F5 treatment.
- Immune function and T-cell numbers were assessed both in vitro and in vivo.
- Results were compared to baseline and potential spontaneous recovery.
Main Results:
- Thymosin F5 increased T-cell numbers in vitro in 3 of 5 patients.
- In vivo treatment with thymosin F5 improved T-cell number and function in 3 of 4 patients.
- While spontaneous improvement is possible, results suggest thymosin F5 efficacy.
Conclusions:
- Thymosin fraction 5 demonstrates potential therapeutic value for immune defects in DiGeorge syndrome.
- Further clinical trials of thymosin F5 therapy are warranted for this patient population.
- Thymosin F5 may offer a safer alternative to fetal thymus transplantation.